Baseline characteristics
infarct
ANTERIOR, INFARCT, TRANSFORMING

CONSORT Flow Chart. PCI: Percutaneous Coronary Intervention; CONSORT: Consolidated Standards of Reporting TrialsFigure Table 
Demographic Data

Large
Note: Large infarct: Anterior, Anteroseptal, Anterolateral, Anterior extensiveSmall infarct: Inferiorthe test used is Mann-Whitney testFigure The trends in the No Revas group showed that all of the No Revas + OMT + Placebo groups had higher MMP-9, NOX2, and TGF-β levels than the No Revas + OMT + Colchicine group both in the Day-1 and Day-5. The analysis between each biomarker showed significant results within No Revas + OMT + Colchicine group versus No Revas + OMT + Placebo in MMP9 (Day-1: p = 0.001; Day-5: p = 0.022), NOX2 (Day-1: p = 0.02; Day-5: p = 0.026), and TGF-β (Day-1: p = 0.00; Day-5: p = 0.00). The exact number of mean ± SD from all biomarkers can be seen in Table 
Analysis of biomarkers between each group during Day-1 and Day-5(*p = < 0.05; ns = not significant
Summary of biomarkers analysis: MMP-9, NOX2, and TGF-β1MMP-9: Matrix Metalloproteinase-9; NOX2: NADPH Oxidase 2; TGF-β1: Transforming Growth Factor Beta 1; SD: Standard Deviation. *p = < 0.05, analyzed with Mann-Whitney analysisWe also compared the standard laboratory test (hemoglobin, leukocyte, thrombocyte, blood urea nitrogen, creatinine serum, aspartate transaminase, and alanine transaminase between each group) in late PCI + OMT + colchicine, late PCI + OMT, No Revas + OMT + colchicine, and No Revas + OMT. There was no significant difference in each group. We also tested the troponin for all of the patients and all of them showed positive results. The data are shown in Table 
Standard laboratory markers